Objective To investigate the clinical effect of rosuvastatin combined with trimetazidine for treating coronary heart disease and its effect on cardiac function. Methods Totally 110 patients with coronary heart disease admitted to our hospital from December 2013 to February 2017 were selected and divided into the two groups. The control group was treated with rosuvastatin, on this basis, the observation group was treated with trimetazidine. Results After treatment, the cardiac function indexes of the two groups were significantly improved, and the observation group was significantly better than the control group ( P< 0. 05 ) . The levels of TC and LDL-C in the observation group were significantly lower than those before treatment, and the observation group was significantly better than the control group ( P< 0. 05 ) . The incidence rate of readmission caused by myocardial infarction and angina pectoris was in the observation group 9. 09%, which was significantly lower than 23. 64% in the control group ( P< 0. 05 ) . Conclusion Rosuvastatin combined with trimetazidine can improve cardiac function in patients with coronary heart disease, the curative effect is remarkable, it is worthy of clinical promotion.%目的 探讨瑞舒伐他汀联合曲美他嗪对冠状动脉粥样硬化性心脏病(简称冠心病)患者心功能的影响及临床疗效.方法 选择2013年12月至2017年2月医院收治的冠心病患者110例,对照组患者给予瑞舒伐他汀,观察组患者在对照组基础上加用曲美他嗪.结果 两组患者治疗后的心功能指标均明显改善,且观察组优于对照组(P<0.05);观察组患者总胆固醇及低密度脂蛋白胆固醇均较治疗前显著降低,且优于对照组(P<0.05);观察组的心肌梗死、心绞痛再入院等发生率为9.09%,低于对照组的23.64%(P<0.05).结论 瑞舒伐他汀联合曲美他嗪能改善冠心病患者的心功能,疗效显著,值得临床推广.
展开▼
